Iressa v BSC (Best Supportive Care) in First Line NSCLC
Launched by ASTRAZENECA · Nov 25, 2005
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically or cytologically confirmed NSCLC
- • NSCLC - locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable to curative surgery or radiotherapy
- • Not suitable for chemotherapy
- • WHO Performance status 2 or 3
- Exclusion Criteria:
- • Newly diagnosed CNS mets
- • Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity
- • Other co-existing malignancies
- • ALT/AST greater than 5 x upper limit of normal
- • ANC less than 1.0 x 109/L or platelets less than 100 x 109/L
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Leeds, , United Kingdom
Bedford Park, , Australia
Halifax, , Canada
Toronto, , Canada
Winnipeg, Manitoba, Canada
Kingston, Ontario, Canada
Newmarket, Ontario, Canada
Oshawa, Ontario, Canada
Ottawa, Ontario, Canada
Sault Ste. Marie, Ontario, Canada
Surrey, British Columbia, Canada
Moncton, New Brunswick, Canada
Mississauga, Ontario, Canada
Den Haag, , Netherlands
Eindhoven, , Netherlands
Birmingham, , United Kingdom
Calgary, Alberta, Canada
Melbourne, , Australia
Randwick, , Australia
Cardiff, , United Kingdom
Kelowna, British Columbia, Canada
Den Bosch, , Netherlands
Newcastle, , Australia
Nova Ves Pod Plesi, , Czech Republic
Zutphen, , Netherlands
Thunder Bay, Ontario, Canada
Concord, , Australia
Birmingham, West Midlands, United Kingdom
Hamilton, Ontario, Canada
Kingston, , Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
London, Ontario, Canada
Amsterdam, Nh, Netherlands
Wolverhampton, , United Kingdom
Chermside, , Australia
Prahran, , Australia
Barrie, Ontario, Canada
Abergavenny, , United Kingdom
Patients applied
Trial Officials
AstraZeneca Iressa Medical Science Director, MD
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials